{"entity":{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","aka":["Invasive carcinoma arising in an IPMN (tubular or colloid type; treated as ductal PDAC)","Invasive carcinoma arising in an IPMN (tubular or colloid type; 10 percent of resections; staged and treated as ductal adenocarcinoma)","IPMN with associated invasive carcinoma","Invasive IPMN","IPMN-associated invasive adenocarcinoma","IPMN-derived pancreatic cancer"],"tldr":"IPMN-associated carcinoma is pancreatic cancer that has grown out of a mucus-producing cyst in the pancreatic duct. Because the cyst is often being watched, the cancer is found smaller and earlier, and about four in ten patients are alive five years after surgery against two in ten for ordinary pancreatic cancer; the advantage belongs to the colloid type, not the tubular type.","summary":"What it is. Intraductal papillary mucinous neoplasms progress through low- and high-grade dysplasia to invasive carcinoma of two main types, tubular (which looks like ordinary ductal adenocarcinoma) and colloid (mucin pools), with a rarer oncocytic type; the 2015 Baltimore consensus asks pathologists to measure the distance between the IPMN and the invasive cancer and to sample the tissue between, because a carcinoma that is merely concomitant (arising separately in the same gland) should be genetically distinct from one associated with the IPMN (Basturk 2015). The parent cyst page carries the Fukuoka and Kyoto surveillance rules; this page is the cancer that surveillance is trying to pre-empt.\n\nHow it differs from its parent. In 1,260 consecutive resections for pancreatic adenocarcinoma, 132 (10 percent) were IPMN-associated and their five-year survival was 42 percent against 19 percent, explained by lower T stage, fewer node metastases, lower grade, fewer positive margins and less perineural and vascular invasion; when any one of those adverse features was present, survival fell to that of ordinary disease (Poultsides 2010). In 61 invasive IPMNs against 570 ductal adenocarcinomas, 62 percent were tubular, 26 percent colloid and 12 percent oncocytic; the favourable outcome (hazard ratio 0.58 after stage matching) held only for colloid and oncocytic carcinomas, while tubular carcinoma was no better than ordinary ductal cancer; colloid carcinomas arose from intestinal-type, mostly main-duct IPMNs and tubular carcinomas from gastric-type, often branch-duct IPMNs (Mino-Kenudson 2011). In a matched comparison of 59 patients, three- and five-year survival were 76 and 68 percent, and tubular histology carried 3.7 times the hazard of death of colloid histology (Yopp 2011).\n\nHow common it is. About 10 percent of resected adenocarcinomas in the Johns Hopkins series; no population count is published.\n\nHow it is treated. Staged by TNM and treated as pancreatic ductal adenocarcinoma: resection (pancreatoduodenectomy or distal pancreatectomy, sometimes total pancreatectomy for main-duct disease throughout the gland) with adjuvant chemotherapy, and lifelong surveillance of any remaining pancreas because IPMN is a field disease (the parent cyst page cites the Kyoto 2024 guideline). Whether colloid-type cancers need the same adjuvant treatment as tubular cancers has not been tested.","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/Intraductal_papillary_mucinous_neoplasm","links":[{"label":"Poultsides, Ann Surg 2010: histopathologic basis for the favourable survival of IPMN-associated invasive adenocarcinoma","url":"https://doi.org/10.1097/sla.0b013e3181cf8a19"},{"label":"Mino-Kenudson, Gut 2011: prognosis of invasive IPMN depends on histological and precursor epithelial subtypes","url":"https://doi.org/10.1136/gut.2010.232272"},{"label":"Yopp, Ann Surg 2011: invasive carcinoma arising in IPMN, matched comparison with ductal adenocarcinoma","url":"https://doi.org/10.1097/sla.0b013e318214bcb4"},{"label":"Basturk, Am J Surg Pathol 2015: Baltimore consensus, revised classification of pancreatic precursor lesions","url":"https://doi.org/10.1097/pas.0000000000000533"},{"label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system","url":"https://doi.org/10.1111/his.13975"}],"tags":["gi","pancreatic","subtype-page"],"related":["pancreatic","ipmn-cystic-precursors","pancreatic-colloid-carcinoma","mcn-associated-carcinoma","resectable-pdac"],"cancers":[],"sections":[],"technologies":["cytotoxic-chemotherapy","histopathology-ihc","pancreatic-surveillance","mri","endoscopic-ultrasound-systems"],"targets":["kras","tp53","smad4"],"drugs":["folfirinox","gemcitabine-nab-paclitaxel","nalirifox"],"companies":[],"institutions":[],"pathways":["ras-mapk","pancreatic-cancer-signalling","p53-cell-cycle"],"terms":["pancreatic-cyst-high-risk-stigmata","panin","whipple","distal-pancreatectomy","resection-margins","tumour-grade"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"group":"gastrointestinal","burden":"About 10 percent of resected pancreatic adenocarcinomas at a high-volume US centre (132 of 1,260, 1995 to 2006); the share of all pancreatic cancers is lower because many are unresectable at diagnosis and the precursor is not always recognisable.","subtypes":["Tubular-type invasive carcinoma in an IPMN (gastric-type, often branch-duct background; behaves like ductal PDAC)","Colloid-type invasive carcinoma in an IPMN (intestinal-type, mostly main-duct background; better outlook)","Oncocytic-type invasive carcinoma (intraductal oncocytic papillary neoplasm background; favourable)","Concomitant ductal adenocarcinoma separate from an IPMN in the same gland (genetically distinct; treated as ordinary PDAC)"],"biomarkers":["Histological type of the invasive component (tubular, colloid, oncocytic) and of the precursor epithelium (gastric, intestinal, pancreatobiliary, oncocytic)","Distance between the IPMN and the invasive carcinoma (associated versus concomitant, Baltimore 2015)","GNAS mutation (IPMN lineage) alongside KRAS; TP53 and SMAD4 changes with progression","CA 19-9 and cyst-fluid CEA before surgery"],"standardOfCare":[{"setting":"Resectable","approach":"Pancreatoduodenectomy, distal pancreatectomy or total pancreatectomy according to the extent of duct involvement, with regional lymphadenectomy and adjuvant chemotherapy as for ductal adenocarcinoma; surveillance of the remnant gland.","refs":["whipple","distal-pancreatectomy","folfirinox","neoadjuvant-adjuvant","pancreatic-surveillance","mri"],"guideline":{"version":"NCCN Guidelines: Pancreatic Adenocarcinoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455"}},{"setting":"Advanced","approach":"Treated as pancreatic ductal adenocarcinoma: resection with adjuvant chemotherapy when removable, the chemotherapy rows of the parent page when not; the parent record carries the trials.","refs":["folfirinox","gemcitabine-nab-paclitaxel","nalirifox"],"guideline":{"version":"NCCN Guidelines: Pancreatic Adenocarcinoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455"}}],"stateOfArt":["The survival advantage of IPMN-associated cancer is explained by earlier stage and by colloid histology rather than by a different disease; tubular-type cancers need the full ductal adenocarcinoma pathway."],"history":[{"year":2010,"title":"Johns Hopkins series: 10 percent of resected adenocarcinomas are IPMN-associated, five-year survival 42 against 19 percent","refs":["whipple"]},{"year":2011,"title":"Colloid versus tubular histology shown to decide the outcome of invasive IPMN","refs":["pancreatic-colloid-carcinoma"]},{"year":2015,"title":"Baltimore consensus separates associated from concomitant carcinoma","refs":["panin"]}],"pipeline":[],"openProblems":["No trial has tested whether colloid-type cancers can be spared adjuvant chemotherapy.","Surveillance still misses cancers: the parent cyst page carries the unresolved questions of when to operate and when to stop watching."],"parent":"pancreatic"},"route":"/cancers/ipmn-associated-carcinoma/","neighbours":{"cancer":[{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/"},{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"},{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/"},{"id":"pancreatic-surveillance","kind":"technology","name":"High-risk pancreatic surveillance (CAPS / PRECEDE)","route":"/technologies/pancreatic-surveillance/"},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/"}],"pathway":[{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/"},{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"term":[{"id":"distal-pancreatectomy","kind":"term","name":"Distal pancreatectomy (removal of the body and tail of the pancreas, usually with the spleen)","route":"/terms/distal-pancreatectomy/"},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/"},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/"},{"id":"panin","kind":"term","name":"Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer","route":"/terms/panin/"},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/"},{"id":"resection-margins","kind":"term","name":"Resection margins (R0 / R1 / R2)","route":"/terms/resection-margins/"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/"}]}}